Related Experiment Video
Updated: Mar 9, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
New evidence for cardiac benefit of postmenopausal hormone therapy
T S Mikkola1, H Savolainen-Peltonen1, M Venetkoski1
1a Obstetrics and Gynecology , University of Helsinki and Helsinki University Hospital , Helsinki , Finland.
Insights
Estradiol-based hormone therapy (HT) can significantly reduce coronary artery disease (CAD) events and mortality in postmenopausal women. Early initiation of HT, especially within 10 years of menopause, maximizes heart protection.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Women's Health
Background:
- Coronary artery disease (CAD) remains a leading cause of death in women.
- Estrogen receptors in coronary arteries suggest a role for estrogen in cardiovascular health.
- Past concerns regarding hormone therapy (HT) safety for CAD prevention have been raised, notably after the Women's Health Initiative (WHI) study.
Purpose of the Study:
- To evaluate the current evidence on estradiol-based hormone therapy (HT) for cardiovascular protection in postmenopausal women.
- To determine optimal timing and strategies for HT use to maximize cardioprotective benefits.
- To reassess the safety of current HT guidelines, particularly regarding intermittent therapy.
Main Methods:
- Review and synthesis of recent epidemiological data from the USA and Europe.
- Analysis of the relationship between estrogen, estrogen receptors, and cardiovascular outcomes.
- Evaluation of the impact of symptom presence (e.g., hot flushes) on HT efficacy.
- Assessment of risks associated with acute withdrawal of estradiol.
Main Results:
- Estradiol-based HT regimens are associated with a significant reduction in CAD events and mortality.
- Initiating HT early in postmenopause (within 10 years) appears crucial for maximal cardioprotective effects.
- The presence of symptoms like hot flushes may indicate enhanced cardiovascular responsiveness to HT.
- Intermittent HT, involving pauses, may increase the risk of potentially fatal CAD events due to acute estradiol withdrawal.
Conclusions:
- Modernized guidelines for hormone therapy (HT) are needed to optimize its use for cardiovascular protection.
- Early initiation of continuous estradiol-based HT is recommended for women seeking CAD prevention.
- Discontinuation or intermittent use of HT may negate cardioprotective benefits and pose risks.
Abstract:
Coronary artery disease (CAD) is still the most common killer of western women. Coronary arteries, expressing estrogen receptors, are a target for estrogen action. Prior to the Women's Health Initiative (WHI) study, postmenopausal hormone therapy (HT) was widely advocated for primary prevention of CAD, but such use was criticized after the WHI publication. However, new data accumulated in the USA and in Europe indicate that the use of estradiol-based HT regimens does not endanger the heart, but rather, it significantly reduces the incidence of CAD events and mortality. This effect may be related to the presence of hot flushes before HT initiation, because they may indicate a greater responsiveness of the cardiovascular system to HT. To get maximal cardioprotective efficacy of HT, a woman should initiate HT as soon as symptoms occur, and preferably within the first 10 postmenopausal years. Recent guidelines for optimal use of HT recommend pauses of HT at 1-2-year intervals to see whether hot flushes and other symptoms still persist. However, new data question the safety of this policy, because acute withdrawals of estradiol from the circulation may predispose to potentially fatal CAD events. All these data support modernized guidelines for optimal HT use.
Related Concept Videos
01:28Menopause
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
01:29Cardiomyopathy V: Interprofessional Care
01:17Exercise and Cardiac Output
Sustained exercise increases the muscles' oxygen demand, which can be...